{"id":106964,"date":"2025-11-13T10:27:57","date_gmt":"2025-11-13T16:27:57","guid":{"rendered":"https:\/\/www.erdheim-chester.org\/?p=106964"},"modified":"2026-01-29T21:32:08","modified_gmt":"2026-01-30T03:32:08","slug":"comprendre-la-maladie-derdheim-chester-le-contexte-moleculaire-et-clinique","status":"publish","type":"post","link":"https:\/\/www.erdheim-chester.org\/fr\/understanding-erdheim-chester-disease-the-molecular-and-clinical-landscape\/","title":{"rendered":"Comprendre la maladie d'Erdheim-Chester : le contexte mol\u00e9culaire et clinique"},"content":{"rendered":"<p><iframe loading=\"lazy\" title=\"Comprendre la maladie d&#039;Erdheim-Chester : le contexte mol\u00e9culaire et clinique\" width=\"1080\" height=\"608\" src=\"https:\/\/www.youtube.com\/embed\/rlS4IVA50rI?feature=oembed\"  allow=\"accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share\" referrerpolicy=\"strict-origin-when-cross-origin\" allowfullscreen><\/iframe><\/p>\n<p>Pr\u00e9sent\u00e9 par le Dr Sam Reynolds, h\u00e9matologue-oncologue, en partenariat avec l\u2019Erdheim-Chester Disease Global Alliance (ECDGA). Cette pr\u00e9sentation explore la complexit\u00e9 mol\u00e9culaire et clinique de la maladie d\u2019Erdheim-Chester (ECD) \u2014 une maladie histiocytaire rare caract\u00e9ris\u00e9e par la surproduction de cellules immunitaires anormales appel\u00e9es histiocytes. S'appuyant sur des collaborations de recherche men\u00e9es par de grands centres m\u00e9dicaux, notamment l'universit\u00e9 du Michigan, la Mayo Clinic, le Dana-Farber et l'universit\u00e9 d'Alabama \u00e0 Birmingham, le Dr Reynolds propose un aper\u00e7u complet des origines de la maladie d'Erdheim-Chester, de sa variabilit\u00e9 et des nouvelles orientations de la recherche.<\/p>\n<p>Through clear visuals and case examples, Dr. Reynolds explains how ECD develops from mutations in monocytes\u2014specialized white blood cells that can transform into histiocytes within tissues. He illustrates how these mutations, often within the MAPK pathway (including BRAF, KRAS, and MAP2K1), disrupt normal cell growth and lead to inflammation, fibrosis, and tissue damage. The discussion also explores how these genetic findings are driving the rise of precision oncology\u2014targeting treatments based on a patient\u2019s specific molecular profile.<\/p>\n<p>Key topics covered in this webinar include:<\/p>\n<ul>\n<li>Comment l'ECD r\u00e9sulte d'anomalies au niveau des monocytes et des histiocytes<\/li>\n<li>Le r\u00f4le des mutations somatiques dans la progression de la maladie<\/li>\n<li>H\u00e9t\u00e9rog\u00e9n\u00e9it\u00e9 clinique : pourquoi il n'y a pas deux patients atteints d'ECD identiques<\/li>\n<li>Progr\u00e8s en mati\u00e8re de th\u00e9rapie cibl\u00e9e et de m\u00e9decine de pr\u00e9cision<\/li>\n<li>Le lien entre l'ECD, l'h\u00e9matopo\u00ef\u00e8se clonale et les cancers secondaires tels que la LAM<\/li>\n<li>L'importance de la recherche continue et de la collaboration avec les patients<\/li>\n<\/ul>\n<p>Le Dr Reynolds souligne que la compr\u00e9hension du profil mol\u00e9culaire de l'ECD permet non seulement d'approfondir les connaissances scientifiques, mais aussi d'am\u00e9liorer la capacit\u00e9 \u00e0 personnaliser les traitements, \u00e0 pr\u00e9dire les r\u00e9sultats et \u00e0 am\u00e9liorer la qualit\u00e9 de vie.<\/p>","protected":false},"excerpt":{"rendered":"<p>Pr\u00e9sent\u00e9 par le Dr Sam Reynolds, h\u00e9matologue-oncologue, en partenariat avec l\u2019Erdheim-Chester Disease Global Alliance (ECDGA). Cette pr\u00e9sentation explore la complexit\u00e9 mol\u00e9culaire et clinique de la maladie d\u2019Erdheim-Chester (ECD) \u2014 une maladie histiocytaire rare caract\u00e9ris\u00e9e par une surproduction de cellules immunitaires anormales appel\u00e9es histiocytes.<\/p>","protected":false},"author":20,"featured_media":113545,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_et_pb_use_builder":"","_et_pb_old_content":"","_et_gb_content_width":"","cybocfi_hide_featured_image":"yes","wds_primary_category":0,"footnotes":"","_links_to":"","_links_to_target":""},"categories":[351],"tags":[5324,5320,5319,5328,5317,5318,5321,5326,4965,4960,5325,5323,5327,5322,4961],"class_list":["post-106964","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-webinar-recordings","tag-braf-mutation","tag-dr-sam-reynolds","tag-ecd-global-alliance","tag-ecd-patient-community","tag-erdheim-chester-disease","tag-erdheim-chester-disease-global-alliance","tag-erdheim-chester-research","tag-hematologic-neoplasms","tag-histiocytic-disorders","tag-mapk-pathway","tag-monocyte-disorders","tag-precision-oncology","tag-rare-blood-cancer-awareness","tag-rare-disease-education","tag-rare-disease-research"],"_links":{"self":[{"href":"https:\/\/www.erdheim-chester.org\/fr\/wp-json\/wp\/v2\/posts\/106964","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.erdheim-chester.org\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.erdheim-chester.org\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.erdheim-chester.org\/fr\/wp-json\/wp\/v2\/users\/20"}],"replies":[{"embeddable":true,"href":"https:\/\/www.erdheim-chester.org\/fr\/wp-json\/wp\/v2\/comments?post=106964"}],"version-history":[{"count":0,"href":"https:\/\/www.erdheim-chester.org\/fr\/wp-json\/wp\/v2\/posts\/106964\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.erdheim-chester.org\/fr\/wp-json\/wp\/v2\/media\/113545"}],"wp:attachment":[{"href":"https:\/\/www.erdheim-chester.org\/fr\/wp-json\/wp\/v2\/media?parent=106964"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.erdheim-chester.org\/fr\/wp-json\/wp\/v2\/categories?post=106964"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.erdheim-chester.org\/fr\/wp-json\/wp\/v2\/tags?post=106964"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}